MDGL
What one share of Madrigal Pharmaceuticals holds
Pharmaceutical Preparations
We are a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (“MASH”), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality.
Madrigal Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $44.47 |
|---|---|
| Profit | −$11.26 |
| Capex (buildings and equipment) | $0.30 |
| Free cash flow | −$7.14 |
| Cash and investments | $12.68 |
| Debt | $14.76 |
| Book value | $22.68 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$40.03 | $0.34 | −$18.71 | — | −$277.67 |
| 2016 | — | −$5.07 | $0.00 | −$3.38 | — | — |
| 2017 | $0.00 | −$2.54 | $0.01 | −$1.83 | — | $12.81 |
| 2018 | $0.00 | −$2.22 | $0.00 | −$1.73 | — | $30.95 |
| 2019 | $0.00 | −$5.45 | $0.01 | −$2.71 | — | $27.00 |
| 2020 | $0.00 | −$13.09 | $0.02 | −$10.22 | — | $15.47 |
| 2021 | $0.00 | −$14.63 | $0.01 | −$11.14 | — | $11.47 |
| 2022 | $0.00 | −$17.23 | $0.01 | −$13.13 | — | $10.90 |
| 2023 | $0.00 | −$17.33 | $0.07 | −$15.11 | — | $20.39 |
| 2024 | $6.69 | −$17.31 | $0.05 | −$16.98 | — | $34.28 |
| 2025 | $33.74 | −$10.15 | $0.02 | −$6.69 | — | $26.39 |